Protocol Ledger

NCT06154252 · Phase II/III · RECRUITING

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Interventional Phase II/III clinical trial protocol NCT06154252 sponsored by Cabaletta Bio in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-20 Enrollment: 74 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06154252
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)74 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06154252
Protocol FieldVerified Registry Value
NCT IdentifierNCT06154252
Consolidated Lead SponsorCabaletta Bio
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment74 participants (ESTIMATED)
Registered Start Date2023-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI